You are here

P&T® Journal contents for November 2010

Features

Health Care and Law
Makers of atypical antipsychotic medications are under scrutiny for promoting the off-label use of these agents, a practice that has led to serious adverse events and has cost the manufacturers billions of dollars in penalties.
Robert I. Field, JD, MPH, PhD
Part 2: Ethical, Legal, and Regulatory Issues
The health care reform bill, privacy rules, health information technology, genetic testing, and a trend toward collaboration among federal agencies indicate that all stakeholders will have to change their business practices in the future.
F. Randy Vogenberg, PhD, RPh; Carol Isaacson Barash, PhD; and Michael Pursel, RPh, MBA
Commentary
With the passage of the Patient Protection and Affordable Care Act, five new categories of hospitals and clinics will be able to buy many drugs at reduced prices.
Stephen Barlas
Meeting Highlights
Sessions of the cardiovascular conference addressed the effect of statins on myocardial infarction, the safety of atopaxar (E5555) in acute coronary syndromes, and a comparison of clopidogrel (Plavix) and Prasugrel (Effient). The Parkinson meeting featured gastrointestinal absorption and the value of paroxetine (Paxil), venlafaxine (Effexor), and ritigotine (Neupro) in patients’ quality of life.
Walter Alexander
Topics include fingolimod capsules (Gilenya) for patients with relapsing multiple sclerosis; pegloticase (Krystexxa), an injectable product for gout; and Beyaz, a formulation of Yaz, an oral contraceptive that includes a folate vitamin to reduce the risk of neural tube defects.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial
Thomas Jefferson University Hospital is working to reduce adverse events by using anticoagulation management, a pharmacy service line approach, and technology to enhance patient safety.
David B. Nash, MD, MBA
Medication Errors
Mistakes in prescribing, dispensing, and administering drugs are more likely when the agent is ordered from a remote location and when procedures are not reviewed.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Meeting the Requirements of the Non-Profit Institutions Act
Changes in the government’s drug pricing program, along with the Non-Profit Institutions Act exemption, may enable hospital pharmacies to buy drugs at a lower cost.
Stephen Barlas
FDA approvals, new drug ­indications, and updates
Drug Forecast
The First Four-Phasic Oral Contraceptive
Natazia, a four-phasic oral contraceptive
Uche Anadu Ndefo, PharmD, BCPS; and Nina Mosely, PharmD Candidate